全网公布的爱泌罗2025年最新价格

Amirol is an important drug for the treatment of interstitial cystitis, and its price and medication information have always attracted much attention. According to the latest information published on the Internet, the price of Amirol will fluctuate in 2025, but will remain stable overall.

The latest price of Amuro in 2025 published on the entire network

The price varies due to various factors such as version, region, purchasing channel and packaging specifications. The price is for reference only. It is currently known that the price of the version of Amilu exported to Türkiye is about US$254 per box, and the specification of a box is 100ngx100 tablets.

The original drug of Almiro is developed and produced by Janssen Pharmaceuticals, Inc. (Johnson & Johnson Pharmaceuticals Company of the United States). It has been approved for marketing in the United States for the treatment of interstitial cystitis. No other versions are currently known.

Amirol Medication Guide

The medication of Amirol must strictly follow the doctor's instructions and drug instructions, and self-medication is not allowed.

Recommended dosage and administration

The recommended dosage of Amirol is 300 mg per day, usually divided into three doses, 100 mg each time. Capsules should be taken at least 1 hour before or 2 hours after a meal to reduce the impact of food on their absorption. Patients should strictly follow the doctor's instructions and drug instructions, and should not increase or decrease the dosage or stop the drug at will.

Medication Precautions

During the course of treatment with Amirol, patients should re-evaluate the improvement of symptoms after 3 months. If no significant improvement is seen and there are no serious adverse reactions, use can be continued. If symptoms improve, it is recommended to continue treatment until symptoms are completely relieved. At the same time, regular review is very important to monitor changes in condition and adjust treatment plans. Patients should undergo regular cystoscopy, cytology examinations and biopsies as arranged by their doctor.

Contraindicated groups of Amirol

Amirol is not suitable for all patients. The following groups should avoid using it or use it with caution.

Patients who are allergic to sodium pentosan polysulfate

Patients who are allergic to Almiral should not use Almiral. Before use, patients should inform their doctor in detail about their allergic history so that the doctor can evaluate whether the drug is suitable for use.

Patients at risk of bleeding

Patients with diseases such as thrombocytopenia and hemophilia, as well as gastrointestinal ulcers, polyps, or diverticula, should avoid the use of Almirol as these diseases may increase the risk of bleeding. Patients with underlying coagulation disorders or other increased bleeding risks should also be used with caution and closely monitored for bleeding.

Patients with renal insufficiency

For patients with renal insufficiency, the dose needs to be adjusted appropriately according to renal function. Patients with mild renal insufficiency (creatinine clearance 60-89 mL/min) do not need to adjust the dose; patients with moderate renal insufficiency (creatinine clearance 30-59 mL/min) should have the dose reduced by half; patients with severe renal insufficiency (creatinine clearance <30 mL/min) should use it with caution, and if necessary, the dose can be reduced or discontinued under the guidance of a doctor.